Bacterial lipopolysaccharide (LPS, endotoxin) is the major constituent of the outer membrane of Gramnegative
bacteria. LPS can cause a variety of immune- and cellular disorders that lead to lethal effects and clinical
manifestations of infectious diseases. Several molecular and cellular in vitro techniques, besides synthesis of analogous
molecules of the LPS active region, have provided insight in the molecular mechanisms of LPS bioactivity in cellular
systems. These advances have facilitated the application of diverse LPS–based molecules in relevant areas such as vaccine
technology, allergen immunotherapy, treatment of immune-related diseases/disorders, LPS-related inflammatory
processes and sepsis. The purpose of this review is to examine the progress in the generation of new LPS-based molecules
and their therapeutic potential.
Keywords: Adjuvant, bacterial LPS, drug development, immune disorders, endotoxin, LPS–based molecules, oxygen delivery, hypoglycemia, hemodynamics, organ dysfunction, Neisseria meningitidis, 3-deoxyoctonoic acid, N-glucosamine.
Rights & PermissionsPrintExport